Description:
The aim of this phase I/II trial is induction of anti leukemic T cell immunity in a clinical
situation of "minimal residual disease". This might be a strategy to immunologically
eradicate the residual leukemia cells. Patients to be included are chronic phase bcr/abl+ CML
(chronic myeloid leukemia) patients in stable cytogenetic and/or molecular remission.
These patients can be included if they have:
1. not achieved a CMR (complete molecular response) or
2. achieved bcr/abl < 10% on qPCR (quantitative polymerase chain reaction) (=MCyR) (Major
cytogenic Response), but less than a CCyR (complete cytogenic Response).
Autologous DC (Dendritic cells), generated under GMP (Good manufacturing conditions)
conditions, are used as a vaccine. These DC constitutively express all putative tumor
antigens. In order to ensure sufficient presentation of distinct CML-related antigens,
particularly in good responders to TKIs, DC are additionally pulsed with peptides from
bcr/abl, WT-1 (Wilms Tumor Protein) and proteinase-3. Monitoring of T cell reactivity against
these peptides can then serve as surrogate marker for anti leukemic immunity induced by the
vaccine. Vaccination is performed with 10^7 DC i.d. (intra dermal) in weeks 1, 3, 5, 8, 11,
14, 17, 20, 23 and 26. KLH (keyhole limpet hemocyanin) is used as an adjuvant for vaccine
preparations in weeks 3, 5 and 8 (and 11).
Title
- Brief Title: DC Vaccination in CML
- Official Title: Dendritic Cells as Autologous Vaccine in Patients With Chronic Myeloid Leukemia
Clinical Trial IDs
- ORG STUDY ID:
CSTI571ADE60
- SECONDARY ID:
2006-006962-41
- NCT ID:
NCT02543749
Conditions
- Myeloid Leukemia, Chronic
Interventions
Drug | Synonyms | Arms |
---|
DC vaccine | | DC vaccine |
Purpose
The aim of this phase I/II trial is induction of anti leukemic T cell immunity in a clinical
situation of "minimal residual disease". This might be a strategy to immunologically
eradicate the residual leukemia cells. Patients to be included are chronic phase bcr/abl+ CML
(chronic myeloid leukemia) patients in stable cytogenetic and/or molecular remission.
These patients can be included if they have:
1. not achieved a CMR (complete molecular response) or
2. achieved bcr/abl < 10% on qPCR (quantitative polymerase chain reaction) (=MCyR) (Major
cytogenic Response), but less than a CCyR (complete cytogenic Response).
Autologous DC (Dendritic cells), generated under GMP (Good manufacturing conditions)
conditions, are used as a vaccine. These DC constitutively express all putative tumor
antigens. In order to ensure sufficient presentation of distinct CML-related antigens,
particularly in good responders to TKIs, DC are additionally pulsed with peptides from
bcr/abl, WT-1 (Wilms Tumor Protein) and proteinase-3. Monitoring of T cell reactivity against
these peptides can then serve as surrogate marker for anti leukemic immunity induced by the
vaccine. Vaccination is performed with 10^7 DC i.d. (intra dermal) in weeks 1, 3, 5, 8, 11,
14, 17, 20, 23 and 26. KLH (keyhole limpet hemocyanin) is used as an adjuvant for vaccine
preparations in weeks 3, 5 and 8 (and 11).
Trial Arms
Name | Type | Description | Interventions |
---|
DC vaccine | Experimental | Autologous DC pulsed with leukemia-associated peptides+adjuvant.
Ten vaccinations over 26 weeks with 10 x 106 freshly thawed DC Intradermal injections (1-2 ml volume) | |
Eligibility Criteria
Inclusion Criteria:
1. Patients with bcr/abl-positive CML in stable cytogenetic / molecular remission after
at least 18 months therapy with tyrosine kinase Inhibitors (TKI). The following groups
of patients will be included:
- complete cytogenetic remission (CCyR), but stable detection of bcr/abl-transcript
on qPCR (at least on two different time points over a period of at least 6
months). A stable molecular remission is assumed, if the difference between the
qPCR values does not exceed a factor 5 (< 0,5log).
- No CCyR, but qPCR for bcr/abl transcript < 10% (= MCyR (Major cytogenetic
Response)) after at least 24 months on 2nd generation TKI therapy.
2. Treatment with a TKI inhibitor and an additional anti leukemic drug is no exclusion
criterion.
3. Age 18-80 years
4. Performance status of 0 or 1 according to WHO index or Karnofsky index >70 %
5. Life expectancy > 18 months
6. Hematological function should be at least partially conserved (platelets count
>50.000/ μl, Hb > 8g/dl)
7. written informed consent
8. No breast feeding
9. if of childbearing potential, negative pregnancy test (serum/urine ß- HCG ( human
chorionic gonadotropin )) and willingness to use highly effective contraceptive
methods (Pearl Index <1, e.g.: birth control pill, loop, hormone implant, transdermal
hormone patch, a combination of two barrier methods [condom and vaginal diaphragm]
sterilisation or sexual abstinence) for the study duration and thereafter as long as
under treatment with antileukemic drugs
Exclusion Criteria:
1. Clinically relevant autoimmune disorders
2. Immunodeficiency syndromes
3. Known allergy to GM-CSF (granulocyte macrophage colony-stimulating factor), TNF-α
(Tumor necrosis factor Alpha) , IL-4 (interleukine 4) or KLH (keyhole limpet
hemocyanin)
4. Pregnancy (absence confirmed by serum/urine ß-HCG) or breastfeeding
5. Women of childbearing age without highly effective contraception
6. Active infectious disease requiring treatment
7. Continuous therapy with corticosteroids or other immunosuppressive drugs
8. Severe psychiatric disorders
9. Organ dysfunction:
- Thrombin Time / Partial Thromboplastin Time > 1,5 x upper normal limit
- creatinine > 2,0 mg/ml
- Bilirubin > 3,0 mg/ml, ALAT/ASAT (Alanine aminotransferase/ aspartate
aminotransferase) > 3x upper normal limit
- pulmonary disfunction (dyspnea at rest or with minimal exertion)
- clinically relevant coronary heart disease or ventricular arrhythmia, congestive
heart failure > grade II NYHA (New York Heart Association)
10. Persons who are detained officially or legally to an official institute
11. Subjects for whom there is concern about compliance with the protocol procedures
12. Present History of substance abuse (drug or alcohol) or any other factor (e.g.,
serious psychiatric condition) that could limit the subject's ability to comply with
study procedures
Maximum Eligible Age: | 80 Years |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | DC toxicity Parameters using CTC (Common toxicity criteria) |
Time Frame: | 30 weeks |
Safety Issue: | |
Description: | Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0 (Treatment: long-term vaccination with peptide-pulsed autologous DC in patients with chronic phase CML who have persistent residual cytogenetic and/or molecular disease after at least 18 months therapy with a tyrosine kinase Inhibitor) |
Secondary Outcome Measures
Measure: | Molecular/cytogenetic Response under vaccination as measured by qPCR for bcr/abl in % IS (International scale) |
Time Frame: | 30 weeks |
Safety Issue: | |
Description: | |
Measure: | T-cell Response: Antigen specific T-cell Response in % CD8+ T-cells for bcr/abl |
Time Frame: | 30 weeks |
Safety Issue: | |
Description: | |
Measure: | T-cell Response: Antigen specific T-cell Response in % CD4+ T-cells for bcr/abl |
Time Frame: | 30 weeks |
Safety Issue: | |
Description: | |
Measure: | T-cell Response: Antigen specific T-cell Response in % CD8+ T-cells for WT-1 (only in HLA-A2+ patients) |
Time Frame: | 30 weeks |
Safety Issue: | |
Description: | |
Measure: | T-cell Response: Antigen specific T-cell Response in % CD8+ T-cells for Proteinase 3 (only in HLA-A2+ patients) |
Time Frame: | 30 weeks |
Safety Issue: | |
Description: | |
Details
Phase: | Phase 1/Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Charite University, Berlin, Germany |
Trial Keywords
Last Updated
August 4, 2021